Analystreport

Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com